These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23457670)

  • 21. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.
    Chung KF
    J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
    Corren J; Castro M; O'Riordan T; Hanania NA; Pavord ID; Quirce S; Chipps BE; Wenzel SE; Thangavelu K; Rice MS; Harel S; Jagerschmidt A; Khan AH; Kamat S; Maroni J; Rowe P; Lu Y; Amin N; Pirozzi G; Ruddy M; Graham NMH; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):516-526. PubMed ID: 31521831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IgE-blocking therapy for difficult-to-treat asthma: a brief review.
    Marshall GD; Sorkness CA
    Manag Care; 2004 Mar; 13(3):45-50. PubMed ID: 15074156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma].
    Kolbin AS; Avdeev SN; Zhuravleva MV; Gomon YM; Balykina YE; Matveyev NV; Proskurin MA; Fedosenko SV
    Ter Arkh; 2019 Dec; 91(12):47-56. PubMed ID: 32598589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future biologic therapies in asthma.
    Quirce S; Bobolea I; Domínguez-Ortega J; Barranco P
    Arch Bronconeumol; 2014 Aug; 50(8):355-61. PubMed ID: 24685200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-IgE in allergic asthma and rhinitis: an update.
    Morjaria JB; Gnanakumaran G; Babu KS
    Expert Opin Biol Ther; 2007 Nov; 7(11):1739-47. PubMed ID: 17961096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
    D'Amato G; Perticone M; Bucchioni E; Salzillo A; D'Amato M; Liccardi G
    Eur Ann Allergy Clin Immunol; 2010 Aug; 42(4):135-40. PubMed ID: 21114196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgE and eosinophils as therapeutic targets in asthma.
    Patel TR; Sur S
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody therapy for the management of severe asthma with eosinophilic inflammation.
    Ohta K; Nagase H; Suzukawa M; Ohta S
    Int Immunol; 2017 Jul; 29(7):337-343. PubMed ID: 28910970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Severe asthma: new therapeutic targets].
    Aubier M
    Bull Acad Natl Med; 2010 Jun; 194(6):1009-19. PubMed ID: 21513135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
    Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
    Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
    Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
    Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
    Mavissakalian M; Brady S
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of omalizumab in the treatment of severe allergic asthma.
    Chapman KR; Cartier A; Hébert J; McIvor RA; Schellenberg RR
    Can Respir J; 2006; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological therapies for eosinophilic asthma.
    Patel SS; Casale TB; Cardet JC
    Expert Opin Biol Ther; 2018 Jul; 18(7):747-754. PubMed ID: 29938543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.
    Holgate S; Buhl R; Bousquet J; Smith N; Panahloo Z; Jimenez P
    Respir Med; 2009 Aug; 103(8):1098-113. PubMed ID: 19362459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.